Observ prosp study of acalabrutinib in CLL therapy in real clinical practice in Belarus - ALICIA(BY)

Inclusion Criteria

• Inclusion Criteria:
• -Age ≥18 years.
• - Confirmed diagnosis of CLL.
• -Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.
• -Treatment-naïve or R/R CLL.
• -Ability and willingness to provide informed consent for study participation.
• Exclusion Criteria:
• -Patients not satisfying any of the inclusion criteria.
• -Prior treatment with any BTK inhibitor.
• -Participation in other ongoing clinical trials.
• -Pregnant or breastfeeding females